9291 can be used in patients with lung cancer, especially if the pathology is adenocarcinoma and the gene sequencing shows a mutated phenotype. If oral 9291 becomes resistant, the targeted drug can be replaced, or the basic, most traditional ERSA is Gefitinib for experimental treatment, and systemic intravenous chemotherapy can be chosen for patients with repeated drug resistance, because adenocarcinoma can be treated with docetaxel, or pemetrexed if it is less effective, and if economic conditions allow, it can be combined with biological The most common metastatic organs are the liver and the skull.